Mark Feinberg
Algemeen Directeur bij International AIDS Vaccine Initiative, Inc.
Profiel
Mark Feinberg currently works at International AIDS Vaccine Initiative, Inc., as President, Chief Executive Officer & Director and Global HIV Vaccine Enterprise, as Director.
Actieve functies van Mark Feinberg
| Bedrijven | Functie | Begin |
|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Algemeen Directeur | - |
Global HIV Vaccine Enterprise
 Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Global HIV Vaccine Enterprise engages in the development of preventive HIV vaccines. The company was founded in June 2003 and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
Global HIV Vaccine Enterprise
Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Global HIV Vaccine Enterprise engages in the development of preventive HIV vaccines. The company was founded in June 2003 and is headquartered in New York, NY. | Commercial Services |
